The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 6, Issue 2, 2004, Pages 133-156

  Buse, John B ^a,c   Tan, M H ^b   Prince, M J ^b   Erickson, P P ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Acarbose; Alpha glucosidase inhibitors; Biguanides; Cholesterol; Fatty acids; Glibenclamide; Gliclazide; Glimepiride; Glipizide; Glyburide; HDL cholesterol triglycerides; LDL cholesterol; Metformin; Miglitol; Nateglinide; Pioglitazone; Repaglinide; Review; Rosiglitazone; Sulphonylurea compounds; Thiazolidinediones; Troglitazone; Type 2 diabetes mellitus; Voglibose

Indexed keywords

ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; CHOLESTEROL; FATTY ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TRIACYLGLYCEROL; UNINDEXED DRUG; VOGLIBOSE;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; DIABETES CONTROL; DOSE RESPONSE; DRUG MECHANISM; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; HUMAN; INFORMATION PROCESSING; LIPID BLOOD LEVEL; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 1242273636     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.00325.x     Document Type: Review

References (90)

1. Howard BV, Howard WJ. The pathophysiology and treatment of lipid disorders in diabetes mellitus. In: Kahn CR, Weir GC eds. Joslin's Diabetes Mellitus, 13th edn. Philadelphia, PA: Lea & Febiger, 1994; 372-396.
2. Barakat HA, Carpenter JW, McLendon VD et al. Influence of obesity, impaired glucose tolerance, and non-insulin dependent diabetes on low density lipoprotein structure and composition: Possible link between hyperinsulinemia and atherosclerosis. Diabetes 1990; 39: 1527-1533.
3. Garber AJ, Karlsson FO. Treatment of dyslipidemia in diabetes. Endocrinol Metab Clin North Am 2001; 30 (4): 999-1010.
4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. Bergman M, Gidez LI, Eder HA. The effect of glipizide on HDL and HDL subclasses. Diabetes Res Clin Pract 1986; 3: 245-248.
7. Campbell IW, Menzies DG, Chalmers J, McBain AM, Brown IRF. One-year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab 1994; 21: 394-400.
8. Zurro Hernandez J, Lavielle R. Is sulphonylurea therapy effective long term? A 3-year study with gliclazide. Curr Med Res Opin 1986; 10: 351-358.
9. Mailhot J. Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study. Clin Ther 1993; 15: 1060-1068.
10. Chen K-W, Juang J-H, Huang H-S, Lin J-D, Huang B-Y, Huang M-J. Effect of gliclazide on plasma lipids and pancreatic beta bell function in non-insulin-dependent diabetes mellitus. Chang Gung Med J 1993; 14 (4): 246-250.
11. Tessier D, Maheux P, Khalil A, Fülöp T. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999; 48: 897-903.
12. Salman S, Salman F, Satman I et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 2001; 16: 296-306.
13. Cathelineau G, de Champvallins M, Bouallouche A, Lesobre B. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: Effects of 2 years of gliclazide treatment - the Diadem Study. Metabolism 1996; 46 (Suppl. 1): 31-34.
14. Waysbort J, Regitz G, Chaimowitz D, Tuval M, Nakash I, Brunner D. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus. Clin Ther 1988; 10: 358-371.
15. Rains SGH, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabet Med 1988; 5: 653-658.
16. Segal P, Feig PU, Scherthaner G et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997; 20: 687-691.
17. Ghazzi MN, Perez JE, Antonucci TK et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-439.
18. Britton ME, Denver AE, Mohamed-Ali V, Yudkin JS. Effects of glimepiride vs. glibenclamide on ischaemic heart disease risk factors and glycaemic control in patients with type 2 diabetes mellitus. Clin Drug Invest 1998; 16: 303-317.
19. Marbury T, Huang W-C, Strange P, Labovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155-166.
20. Damsbo P, Marbury TC, Hatorp V, Clauson P, Müller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-39.
21. Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to matformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
22. Hanefeld M, Bouter KP, Dickinson S, Guitard C. Rapid and short-acting mealtime insulin secretion with nateglinide control both prandial and mean glycemia. Diabetes Care 2000; 23: 202-207.
23. Baron AD, Eckel RH, Schmeiser L, Kolterman OG. The effect of short-term α-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics. Metabolism 1987; 36: 409-415.
24. Jenney A, Proietto J, O'Dea K, Nankervis A, Traianedes K, D'Embden H. Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 1993; 16: 499-502.
25. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen II Study. Am J Med 1997; 103: 483-490.
26. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Diabetes Care 1996; 19: 559-563.
27. Matsumoto K, Yana M, Miyake S et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998; 21: 256-260.
28. Wu M-S, Johnston P, Sheu WH-H et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8.
29. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
30. Hollenbeck CB, Johnston P, Varasteh BB, Chen Y-DI, Reaven GM. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertrigyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabetes Metab 1991; 17: 483-489.
31. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 15: 621-629.
32. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333 (9): 541-549.
33. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-66.
34. Patel J, Anderson J, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1: 165-172.
35. Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 287-294.
36. Raskin P, Rappaport EF, Cole ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284.
37. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
38. Phillips LS, Grunberger G, Miller E, Patwarhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-315.
39. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal triglycerides content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
40. Kaneko T, Baba S, Toyota T et al. Dose finding study of AD-4833 in patients with NIDDM on diet therapy alone -double-blind comparative study on four dosages. Jpn J Clin Exp Med 1997; 74 (5): 1250-1277.
41. Kaneko T, Baba S, Toyota T et al. Clinical evaluation of an insulin resistance-improving drug, AD-4833, in patients with non-insulin dependent diabetes mellitus (NIDDM) on diet therapy alone. Jpn J Clin Exp Med 1997; 74: 1227-1249.
42. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-1611.
43. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
44. Glucotrol® Tablets [package insert]. New York, NY: Pfizer, 1993.
45. Glucotrol XL® Extended Release Tablets [package insert]. New York, NY: Pfizer Inc., 1999.
46. DiaBeta® Tablets [package insert]. Kansas City, MO: Hoechst-Roussel Pharmaceuticals, 1997.
47. Glynase PresTab® Tablets [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Co., 1999.
48. Micronase® Tablets [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Co., 1999.
49. Amaryl® Tablets [package insert]. Kansas City, MO: Hoechst-Roussel Pharmaceuticals, 1997.
50. Prandin® Tablets [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals Inc., 1998.
51. Starlix® tablets [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2001.
52. Precose® Tablets [package insert]. West Haven, CT: Bayer Corp., 1998.
53. Glyset® Tablets [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Co., 1999.
54. Diamicron®. In. Compendium of Pharmaceuticals and Specialties, 36th edn. Ottawa, Ontario, Canada: Canadian Pharmacists Association, 2001; 442-443.
55. Basen® Tablets [prescribing information]. Osaka, Japan: Takeda Chemical Industries, Ltd, 1999.
56. Glucophage®, Glucophage XR® [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, 2000.
57. Avandia® Tablets [package insert]. Philadelphia, PA: SmithKline Beecham Pharmaceuticals, 2000.
58. Actos® Tablets [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America, 1999.
59. Brunzell JD & Chait A. Diabetic dyslipidemia: pathology and treatment. In: Porte D Jr, Sherwin RS eds. Ellenberg and Rifkin's Diabetes Mellitus, 5th edn. Stamford, CT: Appleton & Lange, 1997; 1077-1096.
60. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352L: 854-865.
61. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
62. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992; 15: 193-203.
63. Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW, the Troglitazone Study Group. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. J Clin Endocrinol Metab 1998; 83: 3169-3176.
64. Kumar S, Prange A, Schulze J, Lettis S, Barnett AH. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabet Med 1998; 15: 772-779.
65. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19: 151-156.
66. Maggs DG, Buchanan TA, Burant CF et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 176-185.
67. Khan M, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-711.
68. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazoldinediones. Diabetes Care 2000; 23: 557.
69. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7: 162-169.
70. Boyle PJ, King AB, Olansky L et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396.
71. Parulkar A, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
72. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
73. Pyörälä K, Pedersen TR, Kjekshus J et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-620.
74. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction I patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
75. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
76. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410-418.
77. Rubins HB, Robins SJ, Collins D et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002; 162: 2597-2604.
78. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT. A randomized controlled trial. JAMA 2001; 285: 1585-1591.
79. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910.
80. Austin MA, King MC, Vranizan KM, Krauss RM. The atherogenic lipoprotein phenotype (ALP): a proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506.
81. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992; 12: 1496-1502.
82. Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich J. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb 1991; 11: 64-70.
83. Dobiasova M, Frohlich JJ. Advances in understanding of the role of lecithin cholesterol acyltransferase (LCAT) in cholesterol transport. Clin Chim Acta 1999; 286: 257-271.
84. Dobiasova M, Frohlich JJ. Structural and functional assessment of high-density lipoprotein heterogeneity. Clin Chem 1994; 40: 1554-1558.
85. Tan M-H, Loh K-C, Dobiasova M, Frohlich JJ. Fractional esterification rate of HDL particles in patients with type 2 diabetes. Relation to coronary heart disease risk factors. Diabetes Care 1998; 21: 139-142.
86. Tack CJJ, Smits P, Demacker PNM, Stalenhoef AFH. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21: 796-799.
87. Howard BV, Xiaoren P, Harper I, Foley JE, Cheung MC, Taskinen M-R. Effect of sulfonylurea therapy on plasma lipids and high-density lipoprotein composition in non-insulin-dependent diabetes mellitus. Am J Med 1985; 79 (Suppl. 3B): 78-85.
88. Ovalle F, Bell DSH. Effect of thiazolidinediones on high-density lipoprotein subfractions. Endocr Pract 2002; 8: 102-104.
89. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90 (9): 947-952.
90. Winkler K, Konrad T, Fullert S et al. Pioglitazone reduces atherogenic dense LDL particles in non diabetic patients with arterial hypertension: a double-blind, placebo-controlled study. Diabetes Care 2003; 26: 2588-94.